Supernus Pharmaceuticals Reports Second Quarter 2012 Financial Results Read more about Supernus Pharmaceuticals Reports Second Quarter 2012 Financial Results
Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer Read more about Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer
Supernus Provides Update on the Launch of Its Two Epilepsy Products Trokendi XR(TM) and SPN-804 Read more about Supernus Provides Update on the Launch of Its Two Epilepsy Products Trokendi XR(TM) and SPN-804
Supernus Receives Tentative Approval of Trokendi XR(TM) From FDA Read more about Supernus Receives Tentative Approval of Trokendi XR(TM) From FDA
Supernus Pharmaceuticals Reports First Quarter 2012 Financial Results Read more about Supernus Pharmaceuticals Reports First Quarter 2012 Financial Results
Supernus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering Read more about Supernus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
Supernus Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering Read more about Supernus Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
Supernus Pharmaceuticals Completes $75 Million Non-Recourse Note Offering Secured by Oracea® and Sanctura® XR Royalties Read more about Supernus Pharmaceuticals Completes $75 Million Non-Recourse Note Offering Secured by Oracea® and Sanctura® XR Royalties
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for SPN-804 in Refractory Partial Onset Epileptic Seizures Read more about Supernus Pharmaceuticals Initiates Phase III Clinical Trial for SPN-804 in Refractory Partial Onset Epileptic Seizures
Supernus Pharmaceuticals Initiates Phase IIa Clinical Trial for SPN810 in Conduct Disorder Read more about Supernus Pharmaceuticals Initiates Phase IIa Clinical Trial for SPN810 in Conduct Disorder